In our in vitro studies, using as a model non-invasive human breast cancer MCF-7 cells, we demonstrated that treatment with the inflammatory cytokine IL-1β produces alterations in the regulatory mechanisms of growth and differentiation, which, through an EMT process, transformed the cells to an aggressive phenotype with resistance to anticancer drugs [4,6,7]. This evidence concerns the gene IL1B and breast cancer.